Skip to content
Outlook Therapeutics
-
FDA approves Outlook Therapeutics’ Lytenava as first ophthalmic Bevacizumab for wet AMD
Lytenava contains bevacizumab, an anti-vascular endothelial growth factor (anti-VEGF) antibody that inhibits the growth of abnormal blood vessels that can damage the retina.